After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. The stock was recently discussed on Yahoo Finance as it revealed that Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, IOVA falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $15.77 and fluctuated between $16.05 as its day high and $12.09 as its day low. The current market capitalization of Iovance Biotherapeutics Inc is $4.04B. A total of 63.86 million shares were traded on the day, compared to an average of 8.35M shares.
In the most recent transaction, Rothbaum Wayne P. bought 5,000,000 shares of IOVA for 9.15 per share on Feb 20. After the transaction, the Director now owns 28,067,333 company shares. In a previous transaction on Feb 20, MCPEAK MERRILL A bought 250,000 shares at 9.15 per share. IOVA shares that Director owns now total 320,150.
Among the insiders who bought shares, Dukes Iain D. acquired of 32,000 shares on Feb 20 at a per-share price of $9.15. This resulted in the Director holding 54,000 shares of IOVA after the transaction. In another insider transaction, MCPEAK MERRILL A bought 10,000 shares at $5.56 per share on Sep 18. Company shares held by the Director now total 248,633.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for IOVA in the last 3 months, the mean price target is $24.42 with high estimates of $34.00 and low estimates of $17.00. In terms of 52-week highs and lows, IOVA has a high of $13.41 and a low of $3.21.
As of this writing, IOVA has an earnings estimate of -$0.43 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of -$0.34 per share and a lower estimate of -$0.48. The company reported an EPS of -$0.47 in the last quarter, which was 41.30% higher than expectations of -$0.8.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. IOVA’s latest balance sheet shows that the firm has $504.41M in Cash & Short Term Investments as of fiscal 2021. There were $71.53M in debt and $89.20M in liabilities at the time. Its Book Value Per Share was $2.63, while its Total Shareholder’s Equity was $621.66M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IOVA is Buy with a score of 4.86.
